0001127602-17-019588.txt : 20170526
0001127602-17-019588.hdr.sgml : 20170526
20170526192050
ACCESSION NUMBER: 0001127602-17-019588
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170524
FILED AS OF DATE: 20170526
DATE AS OF CHANGE: 20170526
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bioverativ Inc.
CENTRAL INDEX KEY: 0001681689
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813461310
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 225 2ND AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-663-4400
MAIL ADDRESS:
STREET 1: 225 2ND AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DENNER ALEXANDER J
CENTRAL INDEX KEY: 0001361754
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37859
FILM NUMBER: 17875328
MAIL ADDRESS:
STREET 1: C/O SARISSA CAPITAL MANAGEMENT LP
STREET 2: 660 STEAMBOAT ROAD, 3RD FLOOR
CITY: GREENWICH
STATE: CT
ZIP: 06830
FORMER NAME:
FORMER CONFORMED NAME: Denner Alexander J
DATE OF NAME CHANGE: 20060504
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2017-05-24
0001681689
Bioverativ Inc.
BIVV
0001361754
DENNER ALEXANDER J
C/O BIOVERATIV INC.
225 SECOND AVENUE
WALTHAM
MA
02451
1
Common Stock
2017-05-24
4
P
0
340000
54.16
A
495000
I
See footnotes
Common Stock
2017-05-25
4
P
0
130000
54.9839
A
625000
I
See footnotes
Common Stock
2017-05-26
4
P
0
450000
57.2114
A
1075000
I
See footnotes
Common Stock
5001
D
On May 24, 2017, each of Sarissa Capital Domestic Fund LP, a Delaware limited partnership ("Sarissa Domestic") and Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempt limited partnership ("Sarissa Offshore" and together with Sarissa Domestic, the "Sarissa Funds"), purchased an aggregate of 295,800 and 44,200 shares, respectively, of common stock of Bioverativ Inc.
On May 25, 2017, each of Sarissa Domestic and Sarissa Offshore purchased an aggregate of 113,100 and 16,900 shares, respectively, of common stock of Bioverativ Inc.
On May 26, 2017, each of Sarissa Domestic and Sarissa Offshore purchased an aggregate of 391,500 and 58,500 shares, respectively, of common stock of Bioverativ Inc.
Full information regarding the number of shares purchased at each separate price will be provided upon request by the SEC staff, the issuer or a security holder of the issuer.
This represents the weighted average price for shares purchased at a range between $54.0278 (low) and $54.2631 (high).
This represents the weighted average price for shares purchased at a range between $54.9826 (low) and $54.9994 (high).
This represents the weighted average price for shares purchased at a range between $57.1471 (low) and $57.5297 (high).
Includes (i) 390,871 shares beneficially owned by Sarissa Domestic and (ii) 104,129 shares beneficially owned by Sarissa Offshore.
Includes (i) 503,971 shares beneficially owned by Sarissa Domestic and (ii) 121,029 shares beneficially owned by Sarissa Offshore.
Includes (i) 895,471 shares beneficially owned by Sarissa Domestic and (ii) 179,529 shares beneficially owned by Sarissa Offshore.
Alexander Denner, Ph.D. is the Chief Investment Officer of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
/s/ Alexander Denner
2017-05-26